Also for type 2 diabetes treatment, Sitagliptin is a dipeptidyl peptidase 4 (DDP4) inhibitor that increases the levels of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) [92]. Here, GIP is linked to type 2 diabetes mellitus.